Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Opus Genetics, Inc.NASDAQ: IRD
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $2.14M fell 50.9% year over year, behind the +1.3% change in trailing-twelve-month gross profit. Sequentially, it fell 44.5% from the prior quarter. Over 3 fiscal years it compounded at -29.1% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -50.9% toward the trailing-twelve-month pace of +1.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 14.2M USD
- Year-over-year change
- +29.1%
- 4-year CAGR
- +121.6%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.2M | +29.1% |
| FY2024 | 2024-12-31 | 10.99M | -42.3% |
| FY2023 | 2023-12-31 | 19.05M | -52.2% |
| FY2022 | 2022-12-31 | 39.85M | +6665.7% |
| FY2021 | 2021-12-31 | 589K | — |
Gross Profit vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 gross profit of $5.95M is the 3rd highest of the 10 companies compared; the peer median is -$46K.
- Its year-over-year change of +1.3% is the 6th highest of 9, against a peer median of +62.1%.
- Gross profit amounts to 49.6% of revenue for IRD, versus a peer median of 50.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.58M | +289.3% | — | 52.1% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $5.95M | +1.3% | -29.1% | 49.6% |
| LTM Mar 2026 | -$23.47K | +63.1% | — | — | |
| LTM Mar 2026 | -$24K | +96.8% | — | — | |
| LTM Mar 2026 | -$46K | -4.5% | — | — | |
| LTM Mar 2026 | -$129K | — | — | — | |
| LTM Mar 2026 | -$240K | +97.6% | — | 20.9% | |
| LTM Mar 2026 | -$2.24M | -69.6% | -81.5% | — | |
| LTM Mar 2026 | -$11.28M | -289.4% | -56.0% | 61.2% | |
| Peer median (excluding IRD) | -$46K | +62.1% | -56.0% | 50.2% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M |
| Selling, General & Admin | 8.12M | 7.27M | 11.96M | 18.22M | 21.98M |
| Operating Expenses | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| EBITDA | (56.69M) | 18.22M | (9.97M) | (57.52M) | (48.07M) |
| EBITDA Margin | -9624.3% | 45.7% | -52.3% | -523.3% | -338.6% |
| Operating Income | (22.71M) | 18.23M | (10.56M) | (62.07M) | (38.6M) |
| Operating Margin | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2K | 9K | 1.33M | 0 | 1.47M |
| Other Income / Expenses | (33.99M) | (23K) | 589K | 4.54M | (10.99M) |
| Income Before Tax | (56.69M) | 18.2M | (9.97M) | (57.53M) | (49.59M) |
| Pre-Tax Margin | -9625.3% | 45.7% | -52.4% | -523.4% | -349.3% |
| Income Tax Expense | 0 | 315K | 12K | 0 | 0 |
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Net Margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (Basic) | (3.82) | 0.90 | (0.46) | (2.15) | (0.80) |
| EPS (Diluted) | (3.82) | 0.87 | (0.46) | (2.15) | (0.80) |
| Weighted Avg Shares | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M |
| Weighted Avg Shares (Diluted) | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.